At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 397 enrolled
Drug / intervention
Mebendazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of a New Chewable Tablet of Mebendazole Versus the Swallowable, Standard Tablet of Mebendazole Against Hookworm Infections in Children: a Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Mebendazole for Hookworm Infections. Completed, enrolled 397 participants across 1 site.
Detailed Summary
The rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHookworm Infections
CountriesTanzania
CollaboratorsPublic Health Laboratory Ivo de Carneri
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2019
Primary CompletionOct 2019
TodayJul 2026
First PostedJun 24, 2019
Enrollment StartJul 12, 2019
Primary CompletionOct 9, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.0 years ago
Interventions
Mebendazoledrug
Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.